Table 1.
Characteristics of a cohort of 249 patients with aNSCLC who received nivolumab, pembrolizumab, or atezolizumab in the metastatic setting in MSHS hospitals
| Characteristics | n (%) | TTD | OS | ||
|---|---|---|---|---|---|
| Median (95% CI), mo | p value | Median (95% CI), mo | p value | ||
| All | 249 (100) | 5.6 (3.7–7.8) | 17.4 (11.9–NE) | ||
| Age at PD1/PD‐L1 inhibitor initiation (IQR) | 67.3 (61.3–74.3) | ||||
| Age categories at PD1/PD‐L1 inhibitor initiation, yr | .582 | .961 | |||
| <50 | 7 (2.8) | 3.3 (2.8–NR) | 17.4 (17.4–NE) | ||
| 50–64 | 92 (36.9) | 5.3 (2.6–8.5) | NR (11.2–NE) | ||
| 65–74 | 96 (38.6) | 5.6 (3.7–7.8) | 14.6 (11.2–NE) | ||
| 75+ | 54 (21.7) | 9.7 (3.5–NE) | 15.9 (9.9–NE) | ||
| Gender | .639 | .031 | |||
| Female | 122 (49.0) | 5.6 (3.5–8.5) | NR (16.4–NE) | ||
| Male | 127 (51.0) | 5.6 (3.3–8.8) | 12.5 (9.7–NE) | ||
| Race/ethnicity | .342 | .161 | |||
| White | 110 (44.2) | 4.6 (2.4–7.2) | 11.6 (9.7–NE) | ||
| African American | 75 (30.1) | 7.8 (5.4–NE) | NR (18.4–NE) | ||
| Asian | 24 (9.6) | 4.9 (2.8–NE) | NR (12.6–NE) | ||
| Hispanic | 35 (14.1) | 4.7 (2.6–12.9) | 17.4 (9.9–NE) | ||
| Other race | 4 (1.6) | ‐ | ‐ | ||
| Unknown/missing | 1 (0.4) | ‐ | ‐ | ||
| Histology | .187 | .91 | |||
| Nonsquamous cell carcinoma | 189 (75.9) | 5.6 (3.3–7.3) | 16.4 (11.3–NE) | ||
| Squamous cell carcinoma | 48 (19.3) | 7.9 (4.6–NE) | NR (11.5–NE) | ||
| NSCLS, NOS | 12 (4.8) | 3.4 (1.4–NE) | NR (7.5–NE) | ||
| Smoking status | .014 | .145 | |||
| Current or former smoker | 207 (83.1) | 6.6 (4.9–8.5) | 15.9 (11.5–NE) | ||
| Current smoker | 90 (36.1) | 8.3 (6–12.5) | 19.5 (12.6–NE) | ‐‐ | |
| Former smoker | 117 (47.0) | 5.3 (3.0–7.9) | 11.9 (10.9–NE) | ‐‐ | |
| Never Smoker | 38 (15.3) | 3.5 (2.4–5.1) | NR (13.2–NE) | ||
| Not Reported | 4 (1.6) | ‐ | ‐ | ||
| Line of treatment | .369 | .106 | |||
| 1 | 113 (45.4) | 7.2 (4.4–12.2) | NR (13.2–NE) | ||
| 2 or higher | 136 (54.6) | 5.3 (3.0–7.8) | 14.6 (10.9–NE) | ||
| 2 | 102 (41) | 4.9 (2.8–8.8) | 14.6 (10.5–NE) | ‐‐ | |
| 3 or higher | 34 (13.7) | 5.4 (3.0–8.5) | 11.9 (9.9–NE) | ‐‐ | |
| PD‐L1 status | .569 | .118 | |||
| Negative | 52 (20.9) | 4.9 (3.0–NE) | 18.4 (10.5–NE) | ||
| Positive (>1%) | 78 (31.3) | 6.6 (4.9–12.5) | NR (17.4–NE) | ||
| Positive, 1–49% | 35 (14.1) | 5.3 (2.1–13.4) | NR (17.4–NE) | ‐‐ | |
| Positive, ≥50% | 43 (17.3) | 7.9 (4.9–NE) | NR (12.5–NE) | ‐‐ | |
| Unknown or not tested | 119 (47.8) | 4.7 (2.8–7.8) | 11.6 (9.9–NE) | ||
| EGFR mutation/ALK fusion | .222 | .255 | |||
| Mutation present | 25 (10.0) | 3.5 (2.8–NE) | 8.6 (5.6–NE) | ||
| Mutation absent | 157 (63.1) | 5.6 (3.5–7.3) | 18.4 (11.9–NE) | ||
| Not tested | 67 (26.9) | 7.9 (4.4–NE) | NR (11.5–NE) | ||
| Immunotherapy drug | .186 | .412 | |||
| Atezolizumab | 59 (23.7) | 2.8 (2.1–6.6) | NR (10.9–NE) | ||
| Nivolumab | 84 (33.7) | 6.0 (3.3–12.9) | 11.6 (8.6–NE) | ||
| Pembrolizumab | 102 (41.0) | 7.3 (4.9–12.7) | NR (13.2–NE) | ||
| More than one | 4 (1.6) | ‐ | ‐ | ||
| Concurrent with chemotherapy | .053 | .138 | |||
| No | 201 (80.7) | 4.4 (3.0–6.5) | 15.9 (11.5–NE) | ||
| Yes | 48 (19.3) | 8.3 (7.2–NR) | NR (11.6–NE) | ||
p values were based on log‐rank test.
Abbreviations: ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; IQR, interquartile range; MSHS, Mount Sinai Health System; NE, not estimable; NOS, not otherwise specified NR, not reached; NSCLC, non‐small cell lung cancer; PD‐1, programmed cell death one; PD‐L1, programmed cell death ligand one; ‐ not computed due to small sample size within group; ‐‐ subgroup, p values were computed from the higher level grouping.